Saturday 17 October 2026
Export CLGN’s income statement to Excel — free account
CollPlant Biotechnologies Ltd. Sponsored ADR
CLGN Healthcare Biotechnology
CollPlant Biotechnologies Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, up 360.4% from fiscal 2024. In the quarter to June 2026, revenue fell 39.7%, EPS grew 32.5% and free cash flow grew 5.08%, each against the same quarter a year earlier.
3.60
0.08
−2.17%
Follow CLGN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 4 | 2 | 2 |
| (92.74%) | (117.56%) | (151.99%) | (161.98%) | ||
| (66.57%) | (77.90%) | (99.53%) | (101.59%) | ||
ROIC |
(1,612.55%) | (5,478.53%) | (3,125.00%) | 0.00% | |
Return on Tangible Assets |
(140.76%) | (207.46%) | (300.55%) | (509.49%) | |
Average Days of Receivables |
37.46 | 34.48 | 218.62 | 464.86 | |
Free Cash Flow per Share |
(7.87) | (7.74) | (8.24) | (7.76) | |
Free Cash Flow |
(10.02) | (9.45) | (11.33) | (11.20) | |
Capital Expenditures |
(0.07) | (0.03) | (0.02) | (0.01) | |
| Other line items | |||||
Cash ROIC |
(55.25%) | (78.51%) | (119.06%) | (189.99%) | |
Accounts Receivable Turnover |
7.23 | 5.88 | 1.16 | 0.83 | |
Accounts Payable Turnover |
1.12 | 1.13 | 1.37 | 3.24 | |
Inventory Turnover |
1.84 | 1.65 | 1.42 | 2.45 | |
Average Days of Payables |
246.52 | 266.65 | 240.68 | 69.68 | |
Days of Inventory on Hand |
215.41 | 250.47 | 257.36 | 146.98 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
353.54% | 345.30% | 1,994.86% | 2,173.58% | |
Selling, General and Administrative Expense of Revenue |
206.75% | 203.80% | 1,186.63% | 1,405.66% | |
Share Based Compensation of Revenue |
58.22% | 42.13% | 204.88% | 191.51% | |
Interest Coverage |
— | — | — | (30.26) | |
Operating CF/Net income |
0.82 | 0.82 | 0.86 | 0.89 | |
Depreciation/Fixed assets |
0.57 | 0.62 | 0.69 | 0.81 | |
Capex/Depreciation |
(0.07) | (0.03) | (0.03) | (0.01) | |
Revenue per Share |
1.95 | 1.94 | 0.28 | 0.22 | |
Operating CF per Share |
(7.82) | (7.72) | (8.22) | (7.76) | |
Capex per Share |
(0.05) | (0.02) | (0.02) | (0.01) | |
Capex to Sales |
0.03 | 0.01 | 0.06 | 0.03 |
Columns are period end dates · fundamentals updated 6 Oct 2026